Literature DB >> 12584673

Efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental Streptococcus spp and Staphylococcus aureus intramammary infections in lactating dairy cows.

Barbara E Gillespie1, Hugh Moorehead, Phillip Lunn, Henry H Dowlen, David L Johnson, Ken C Lamar, Mark J Lewis, Susan J Ivey, John W Hallberg, S Ted Chester, Stephen P Oliver.   

Abstract

Fifty-one chronically infected lactating dairy cows were used to evaluate the efficacy of extended pirlimycin therapy regimens for treatment of intramammary infections by environmental Streptococcus spp and Staphylococcus aureus. Cows (n = 47) with one or more infected mammary quarters were blocked by parity and randomly allocated to one of three groups for treatment with pirlimycin (50 mg/mammary quarter) as follows: one treatment per day for 2 days (n = 36 infected mammary quarters); one treatment per day for 5 days (n = 36 infected mammary quarters); and one treatment per day for 8 days (n = 20 infected mammary quarters). Four cows with nine infected mammary quarters were included as untreated controls. Milk samples from each mammary quarter were collected 7 days before treatment, immediately before treatment, and weekly for 4 weeks after the final treatment for microbiological evaluation. A bacteriologic cure was defined as a treated, infected quarter that was bacteriologically negative for the presence of previously identified bacteria at weekly intervals after treatment. Efficacy of pirlimycin therapy against intramammary infections caused by environmental Streptococcus spp and S. aureus was 44.4%, 61.1%, and 95.0% for the 2-, 5-, and 8-day treatment regimens, respectively. None of the infections in the untreated control quarters was cured. Significant differences in efficacy were detected between all pirlimycin groups and the untreated control group, between the 8- and 2-day treatment regimens, and between the 8-day and 5-day treatment regimens (P < or = .05). Results of this study indicate that extended pirlimycin therapy was effective in eliminating intramammary infections caused by environmental streptococci and S. aureus in lactating dairy cows.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12584673

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  9 in total

1.  Efficacy of conventional and extended intra-mammary treatment of persistent sub-clinical mastitis with cefquinome in lactating dairy cows.

Authors:  Reza Kasravi; Mahmoud Bolourchi; Nima Farzaneh; Hesam A Seifi; Abbas Barin; Parviz Hovareshti; Faramarz Gharagozlou
Journal:  Trop Anim Health Prod       Date:  2011-03-29       Impact factor: 1.559

Review 2.  Mastitis therapy and antimicrobial susceptibility: a multispecies review with a focus on antibiotic treatment of mastitis in dairy cattle.

Authors:  John Barlow
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-09       Impact factor: 2.673

3.  Efficacy of extended intramammary ceftiofur therapy against mild to moderate clinical mastitis in Holstein dairy cows: a randomized clinical trial.

Authors:  Geoffrey Truchetti; Emile Bouchard; Luc Descôteaux; Daniel Scholl; Jean-Philippe Roy
Journal:  Can J Vet Res       Date:  2014-01       Impact factor: 1.310

4.  Efficacy of a 5-day extended therapy program during lactation with cephapirin sodium in dairy cows chronically infected with Staphylococcus aureus.

Authors:  Jean-Philippe Roy; Luc DesCôteaux; Denis DuTremblay; Francis Beaudry; Johanne Elsener
Journal:  Can Vet J       Date:  2009-12       Impact factor: 1.008

5.  Protective effects of kaempferol on lipopolysaccharide-induced mastitis in mice.

Authors:  Rongfeng Cao; Kaiqiang Fu; Xiaopei Lv; Weishi Li; Naisheng Zhang
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

6.  In vitro antibiotic susceptibility and biofilm production of Staphylococcus aureus isolates recovered from bovine intramammary infections that persisted or not following extended therapies with cephapirin, pirlimycin or ceftiofur.

Authors:  Céline Ster; Valérie Lebeau; Julia Leclerc; Alexandre Fugère; Koui A Veh; Jean-Philippe Roy; François Malouin
Journal:  Vet Res       Date:  2017-09-21       Impact factor: 3.683

7.  Indirubin Treatment of Lipopolysaccharide-Induced Mastitis in a Mouse Model and Activity in Mouse Mammary Epithelial Cells.

Authors:  Jin-Lun Lai; Yu-Hui Liu; Yong-Chong Peng; Pan Ge; Chen-Fei He; Chang Liu; Ying-Yu Chen; Ai-Zhen Guo; Chang-Min Hu
Journal:  Mediators Inflamm       Date:  2017-02-01       Impact factor: 4.711

8.  Therapy of Subclinical Mastitis during Lactation.

Authors:  Scott McDougall; Laura M Clausen; Hassan M Hussein; Chris W R Compton
Journal:  Antibiotics (Basel)       Date:  2022-02-07

9.  Comparison of Immediate Blanket Treatment versus a Delayed Pathogen-Based Treatment Protocol for Clinical Mastitis Using an On-Farm Culture Test at a Commercial German Dairy Farm.

Authors:  Stefan Borchardt; Wolfgang Heuwieser
Journal:  Antibiotics (Basel)       Date:  2022-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.